BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260512T130000
DTEND;TZID=America/New_York:20260512T140000
DTSTAMP:20260422T172046
CREATED:20260414T151231Z
LAST-MODIFIED:20260414T151307Z
UID:72709-1778590800-1778594400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Octapharma - Addressing Heavy Menstrual Bleeding in von Willebrand Disease: Clinical Insights and the Role of wilate®
DESCRIPTION:Date: Tuesday\, May 12th\, 2026\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n \n  \nWEBINAR TOPIC:\nAddressing Heavy Menstrual Bleeding in von Willebrand Disease: Clinical Insights and the Role of wilate® \nOBJECTIVES: \n\nHeavy menstrual bleeding (HMB) is one of the most common and underrecognized manifestations of von Willebrand disease (VWD) and represents a significant cause of iron deficiency and iron deficiency anemia in affected women. Chronic blood loss associated with HMB can lead to fatigue\, impaired cognitive and physical functioning\, reduced quality of life\, and increased healthcare utilization. Despite its prevalence\, both VWD and iron deficiency related to HMB are frequently underdiagnosed and undertreated.\nThis webinar will provide a focused clinical overview of HMB in the context of VWD\, emphasizing the interconnected relationship between abnormal bleeding and iron deficiency. Participants will review the burden of disease\, diagnostic considerations\, and treatment goals aimed at controlling bleeding while addressing its systemic consequences. The program will also highlight Wilate®\, a VWF/FVIII concentrate\, including its clinical profile\, supporting evidence\, and practical application in the management of HMB associated with VWD. Finally\, the webinar will explore Wilate’s clinical and therapeutic value proposition\, with an emphasis on optimizing outcomes and improving quality of life for women living with VWD-related HMB.\n\nAUDIENCE:\nAll HTC Staff. \nSPEAKER: \n \nClaudio Sandoval\, MD – Senior Director\, Scientific and Medical Affairs – Hematology Octapharma USA \nClaudio Sandoval is the Director of Scientific & Medical Affairs at Octapharma. Before his current role he was a pediatric hematologist-oncologist for 30 years caring for children with bleeding disorders\, cancer\, sickle cell disease\, and other maladies. Claudio graduated from New York Medical College and trained at Schneider Children’s Hospital in New Hyde Park\, NY and St. Jude Children’s Research Hospital in Memphis\, TN.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-octapharma-addressing-heavy-menstrual-bleeding-in-von-willebrand-disease-clinical-insights-and-the-role-of-wilate/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR